Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
News
1/22/2025
Fosun Pharma’s Bid to Privatize Henlius Fails After Shareholder Rejec...
1/22/2025
Innovent Advances PD-1/IL-2α-Bias Bispecific Antibody IBI363 into Pha...
1/22/2025
YolTech to Initiate a Clinical Trial of FIC Bone Marrow-Targeted In V...
1/22/2025
Shanghai Bao Pharma Files for IPO on HKSE
1/22/2025
Qyuns Thera Secures CSRC Approval for Full H-share Circulation
1/21/2025
China's Biopharma R&D Expands Global Influence in 2024
1/21/2025
China's BMI Fund Reports Balanced Budget and Surplus for 2024
1/21/2025
ArriVent Enters Exclusive License with Lepu Biopharma for MRG007, an A...
1/21/2025
Sichuan Biokin Refiles for Hong Kong IPO Following Lapsed Application
1/21/2025
China-based Ascentage Pharma Targets $149M in US IPO
1/21/2025
NiKang Does First Patient in a Phase 1b/2 Study of NKT2152 in Combo fo...
1/21/2025
CARsgen's Allogeneic CD38 CAR-T Therapy Administers First Dose in Inve...
1/21/2025
Zai Lab's NDA for Schizophrenia Treatment KarXT Accepted in China
1/21/2025
China to Solicit Feedbacks on Improving Centralized Drug Procurement ...
1/21/2025
Fermion and Simcere Join Forces to Develop Non-Opioid Analgesic
1/21/2025
IVIEW Thera Completes Series A++ Financing to Advance Ophthalmology Pi...
1/21/2025
NMPA Approves Two Homegrown Oncology Therapies for Lung and Ovarian Ca...
1/20/2025
JOINN Biologics Acquires Lonza's Large Molecule CDMO Facility in Guang...
1/20/2025
NMPA Expands Label for Genrix Bio's Xeligekimab in Radiographic AS
1/20/2025
NMPA Expands Label for Kelun-Biotech's Tagitanlimab in First-Line NPC ...
1/20/2025
InnoCare and KeyMed Jointly Enter License Deal with Prolium for CD20xC...
1/20/2025
Junshi and LEO Enter Commercialization Partnership for Toripalimab in ...
1/20/2025
InflamaX Secures Pre-A Investment for Immuno-Inflammatory Research
1/17/2025
Daiichi Sankyo Submits NDA for Pexidartinib (PLX3397) in China as the ...
1/17/2025
Simnova and Orna Expand Partnership to Include BCMA-Targeted RNA Thera...
1/17/2025
Bivision Secures ~CNY 100M in Series A+ Financing, Accelerates Targete...
1/16/2025
Hengrui Pharma Poised for Global Expansion, Eyes More Deals
1/16/2025
Menarini and Insilico Forge Strategic Partnership to Address Unmet Nee...
1/16/2025
Alphamab Advances Oncology Pipeline with Phase 2 Trial of TROP-2/HER3 ...
1/16/2025
Conjustar Biotech Completes CNY 100M Series Pre-A+ Financing
Page:
25
/
53
Total number of articles:
1570
:
[First]
[<<]
[23]
[24]
[25]
[26]
[27]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit